Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 β-lactamase

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Compain, Fabrice ^a,b,c,d   Arthur, Michel ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Avibactam; Carbapenemase; Ceftazidime; KPC 2; lactamase inhibitor

Indexed keywords

AMPICILLIN; AVIBACTAM; AZTREONAM; BETA LACTAMASE; CARBAPENEMASE; CEFTAZIDIME; CEFTRIAXONE; CLAVULANIC ACID; IMIPENEM; KANAMYCIN; KLEBSIELLA PNEUMONIAE CARBAPENEMASE TYPE 2 BETA LACTAMASE; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CARBAMOYLATION; CATALYSIS; DILUTION; GENETIC BACKGROUND; HYDROLYSIS; IN VITRO SELECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RATE CONSTANT; REVERTANT; WILD TYPE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 85022066527     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00451-17     Document Type: Article

References (21)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25:682–707. https://doi.org/10.1128/CMR.05035-11.
2. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevic AT, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae Working Group. 2017. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 17:153–163. https://doi.org/10.1016/S1473-3099(16)30257-2.
3. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S, Network Eu S-I, Grundmann H, Pantosti A, Rossolini GM. 2014. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill 19:pii=20939. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId20939.
4. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160–201. https://doi.org/10.1128/CMR.00037-09.
5. Papp-Wallace KM, Bonomo RA. 2016. New beta-lactamase inhibitors in the clinic. Infect Dis Clin North Am 30:441–464. https://doi.org/10.1016/j.idc.2016.02.007.
6. Sader HS, Castanheira M, Flamm RK. 2017. Antimicrobial activity of ceftazidime-avibactam against Gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. medical centers, 2011 to 2015. Antimicrob Agents Chemother 61:e02083-16. https://doi.org/10.1128/AAC.02083-16.
7. Lahiri SD, Bradford PA, Nichols WW, Alm RA. 2016. Structural and sequence analysis of class A beta-lactamases with respect to avibactam inhibition: impact of Ω-loop variations. J Antimicrob Chemother 71: 2848–2855. https://doi.org/10.1093/jac/dkw248.
8. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618. https://doi.org/10.1093/cid/ciw636.
9. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
10. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/ avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother 70:2279 –2286. https://doi.org/10.1093/jac/dkv094.
11. 132G in the conserved SDN motif. Antimicrob Agents Chemother 61:e02510-16. https://doi.org/10.1128/AAC.02510-16.
12. Clinical and Laboratory Standards Institute. 2015. Methods for dilution susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Bebrone C, Moali C, Mahy F, Rival S, Docquier JD, Rossolini GM, Fastrez J, Pratt RF, Frere JM, Galleni M. 2001. CENTA as a chromogenic substrate for studying beta-lactamases. Antimicrob Agents Chemother 45: 1868–1871. https://doi.org/10.1128/AAC.45.6.1868-1871.2001.
14. Frère JM, Dormans C, Duyckaerts C, De Graeve J. 1982. Interaction of beta-iodopenicillanate with the beta-lactamases of Streptomyces albus G and Actinomadura R39. Biochem J 207:437–444. https://doi.org/10.1042/bj2070437.
15. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663–11668. https://doi.org/10.1073/pnas.1205073109.
16. Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH. 2015. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 59:5793–5797. https://doi.org/10.1128/AAC.00548-15.
17. Spellberg B, Bonomo RA. 2016. Ceftazidime-avibactam and carbapenem-resistant Enterobacteriaceae: “we’re gonna need a bigger boat.” Clin Infect Dis 63:1619–1621. https://doi.org/10.1093/cid/ciw639.
18. KPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agent Chemother, 61:e02534-16. https://doi.org/10.1128/AAC.02534-16.
19. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324–5330. https://doi.org/10.1128/AAC.00678-15.
20. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. In vitro selection of meropenem resistance among ceftazidime-avibactam resistant, meropenem susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother, 61:e00079-17. https://doi.org/10.1128/AAC.00079-17.
21. Soroka D, Ourghanlian C, Compain F, Fichini M, Dubée V, Mainardi J, Hugonnet J, Arthur M. 2017. Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate. J Antimicrob Chemother 72:1081–1088. https://doi.org/10.1093/jac/dkw546.